Baxter International Inc. with ticker code (BAX) have now 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 63.2 and 40 with the average target price sitting at $47.94. Now with the previous closing price of $43.25 and the analysts are correct then we can expect a percentage increase in value of 10.8%. Also worth taking note is the 50 day moving average now sits at $40.47 while the 200 day moving average is $51.32. The company has a market capitalization of $22,895m. Company Website: https://www.baxter.com
The potential market cap would be $25,378m based on the market consensus.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules; and a collaborative research agreement with Miromatrix Medical Inc. to develop treatments for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is based in Deerfield, Illinois.
The company has a dividend yield of 2.66% with the ex dividend date set at 23-2-2023 (DMY).
